drugset
drugset / Trial / NCT03665129

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

NCT03665129 ↗

Phase 1 Terminated 73 enrolled Innate Pharma AstraZeneca · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.

Timeline

Start
2018-09-07
Primary completion
2021-02-24
Completion
2021-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Avdoralimab Monoclonal antibody — —
Subject Durvalumab Monoclonal antibody — —

Indications

cancer